Pyridoclax is primarily investigated for its potential in cancer therapy, particularly as an inhibitor of anti-apoptotic proteins like MCL-1. By targeting these proteins, it promotes programmed cell death in cancer cells, making it a promising candidate for treating malignancies resistant to conventional therapies. Its application is being explored in preclinical and clinical studies to evaluate its efficacy in various cancer types, including hematologic cancers and solid tumors. Additionally, researchers are examining its potential in combination therapies to enhance the effectiveness of existing treatments.